Table 2 Patient characteristics for the multivariate Fine–Gray model: complete data cohort in training and validation datasets.

From: Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice

Variable

Training data (N = 14,781)

Validation data (N = 29,727)

 

N

%

N

%

Racea

    

 White

10,853

73

16,812

57

 Black

1391

9

1303

4

 Hispanic

1767

12

784

3

 Other

770

5

785

3

 Unknown

0

0

10,043

34

Age

    

 <40

1582

11

1913

6

 40–69

11,351

77

22,151

75

 ≥70

1848

12

5663

19

Menopausal statusb

    

 Premenopausal

5182

35

17,332

58

 Postmenopausal

9599

65

12,395

42

Anatomic stage

    

 I

7688

52

16,607

56

 IIA

3694

25

8327

28

 IIB

1870

13

3331

11

 IIIA–IIIB

1076

7

737

3

 IIIC

453

3

725

2

Nuclear gradec

    

 1

1885

13

6723

23

 2

6627

45

13,884

47

 3

6269

42

9120

31

ER statusd

    

 Positive

11,623

79

24,646

83

 Negative

3154

21

5077

17

 Unknown

4

0

4

0

PR statusd

    

 Positive

9790

66

21,827

74

 Negative

4944

33

7856

27

 Unknown

47

0

44

0

Hormone receptor (HR) statuse

    

 HR+c

11,888

80

24,989

84

 HR−d

2893

20

4738

16

HER2 statusd,f

    

 Positive

1175

8

1086

4

 Negative

13,606

92

28,641

96

Biomarker subgroups

    

 TNBC

2431

16

4401

15

 HR+/HER2–

11,175

76

24,240

82

 HR+/HER2+e

713

5

749

3

 HR−/HER2+

462

3

337

1

Chemotherapyf

    

 TNBC

1914

79

3459

79

 HR+/HER2−

5035

45

8866

37

 HR+/HER2+

657

92

748

100

 HR−/HER2+

426

92

335

99

  1. aFor NCCN data, race background and ethnicity variables were used to obtain this variable.
  2. bClinically defined based on history; if not recorded, age is considered (≥60: postmenopausal; <60: premenopausal).
  3. cHistologic grade or nuclear grade (if histologic grade is not available); Training Data, HG (n = 4724); NG (n = 10,057); Validation Data, HG (n = 29,466); NG (n = 12,434).
  4. dBiomarker definitions in database are reflective of evolution of national guidelines28,38,54,55,56.
  5. eHR+:ER+ or PR+; HR−: ER− and PR−.
  6. fAll HER2+ patients included in the multivariate analysis received adjuvant trastuzumab.
Back to article page